Retatrutide vs Tirzepatide: Complete 2026 Comparison
Side-by-side comparison of Retatrutide and Tirzepatide: mechanism, common use cases, dosing protocols from named experts, vendor availability, and expert opinion. Both are framed as research compounds.
TL;DR Table
| Factor | Retatrutide | Tirzepatide |
|---|---|---|
| Class | PEPTIDE | PEPTIDE |
| Aliases | ["Retta", "Reddit (slang misspelling in transcript)"] | ["Mounjaro"] |
| Mechanism | n/a | n/a |
| What it's researched for | Triple agonist of GLP-1, GIP, and glucagon receptors used for appetite suppression and fat loss, but can blunt dopamine/serotonin reward signaling. | Dual GLP-1/GIP receptor agonist that suppresses appetite and slows gastric emptying; favorable fat loss in deficit but favorable fat storage in surplus. |
| Dosing mentions tracked | 178 | 58 |
| Vendor recs tracked | 37 | 14 |
| PubMed papers | 15 | 15 |
Mechanism Comparison
What Each is Researched For
Retatrutide research areas
Triple agonist of GLP-1, GIP, and glucagon receptors used for appetite suppression and fat loss, but can blunt dopamine/serotonin reward signaling.
Tirzepatide research areas
Dual GLP-1/GIP receptor agonist that suppresses appetite and slows gastric emptying; favorable fat loss in deficit but favorable fat storage in surplus.
Dosing Mention Comparison
Retatrutide dosing
- Speaker 1: Speaker 1 reported using a low dose of retatrutide alongside diet and training for nutrient partitioning and muscle-building support. (00:00:09)
- speaker_1: Speaker reported post-show use during the reverse phase for regulation/control and setting up the off-season. (00:00:22)
- speaker_1: Speaker suggests Retatrutide may be more effective post-show during the reverse phase for regulation/control and setting up the off-season. (00:00:22)
- Unknown speaker: Suggested use post-show during the reverse phase for regulation/control and setting up the off-season. (00:00:22)
- Speaker 1: Suggested use post-show in the reverse phase for regulation/control and setting up the off-season. (00:00:22)
Tirzepatide dosing
- Speaker 1: User reports being at the maximum tirzepatide dose of 15 mg per week and asks whether they can stay at 15 mg indefinitely. (00:00:01)
- Speaker 1: Speaker 1 reported that for nausea or intolerance, reducing to the lowest previously tolerated dose rather than increasing helped manage... (00:00:01)
- Speaker 1: Speaker 1 reported: Tirzepatide dose was kept the same while an experimental amylin shot, eloralintide, was added on top. (00:00:08)
- Speaker 1: Speaker 1 reported: Tirzepatide initiated at 2.5 mg; one patient titrated to 3.5 mg rather than escalating to the standard 5 mg dose. (00:00:09)
- Speaker 1: Dose escalation discussed in relation to returning food chatter; speaker argues food choices may help maintain the lowest effective dose. (00:00:12)
Side Effect Notes
Anecdotal reports for both compounds vary by route, dose, and individual. Neither should be treated as an approved medication. Consult a qualified clinician.
When To Choose Which
Comparison depends on research question, available source quality, and individual risk tolerance. See the full profiles for Retatrutide and Tirzepatide for context-specific details.
Can You Stack Them?
Stacking decisions should be evaluated by qualified professionals with attention to dose attribution, source quality, and outcome tracking. This page is a research aggregator and does not recommend stacking protocols.
FAQ
Which has more research?
Retatrutide has 15 PubMed citations indexed; Tirzepatide has 15.
Which has more vendor coverage?
Retatrutide: 37 tracked vendor recommendations. Tirzepatide: 14.
Are they approved drugs?
Both are framed on this site as research compounds. Verify current FDA status and state-specific rules before any decision.
Where do I read more?
See Retatrutide and Tirzepatide for full profiles with all dosing mentions and PubMed citations.